BIOCQ Stock — Biocept Inc.

Biocept Inc. (BIOCQ)

Updated October 14, 2026.

BIOCQ is a Stock. Total return is -100.0% over the past 12.7 years, 543.6 points behind SPY at 443.6%.

Biocept was a molecular oncology diagnostics company that developed blood and cerebrospinal fluid assays to identify rare tumor cells and detect tumor DNA in cancer patients, helping physicians identify treatment options and monitor disease progression across solid tumors including lung, breast, and colorectal cancers. The company filed for Chapter 7 liquidation in October 2023 and does not currently distribute to shareholders. This security is no longer an operating business.

BIOCQ performance versus SPY

Price and return data through 2026-10-14.

Total return is -100.0% over the past 12.7 years, 543.6 points behind SPY at 443.6%. Over the past year its total return — price change plus distributions reinvested — is 200.0%. Its deepest 1-year drawdown was 95.0%.

BIOCQ key facts

Asset type

Stock

Asset class

Equity

Inception date

02/05/2014

Distribution frequency

None

Last close

$0.0003 (stale; as of 2026-10-14)

Market cap

$788

Average volume

644.0

Payment date

09/08/2020

Payout ratio

0.0%

EPS

$-111.70

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BIOCQ risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 95.0%.

Who may consider BIOCQ — and who may not

It is a weaker fit for investors who need monthly cash flow (BIOCQ does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BIOCQ

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions